News
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental
laser manufacturer and distributor, and Cefla Dental Group, a leading
Italian dental equipment manufacturer, today announced that the
companies have entered a definitive three-year agreement making
BIOLASE a distributor of Cefla's NewTom Cone Beam 3D imaging products
in the U.S. and Canada. The NewTom products are well respected in the
medical and dental communities and considered among the highest
quality 3D dental imaging products in the world.
Under the terms of the agreement, BIOLASE will be the exclusive
distributor for dentists, dental schools and dental clinics, and
non-exclusive for certain other medical markets.
NewTom's Cone-Beam-Computed-Tomography (CBCT) is a compact version of
standard CT imaging that uses a cone-shaped X-ray beam to obtain a
multitude of radiographs that construct digital 3D models of
maxillofacial anatomies. Some of the advantages compared to
traditional CT scanners include less radiation, faster scan times and
a more comfortable patient experience.
The NewTom 3D imaging products are typically used in highly complex
dentistry cases by periodontists, endodontists and oral surgeons where
more involved and higher accuracy images are needed. They are
increasingly being adopted by general practitioners for use in placing
implants. The current installed base of NewTom in North America and
worldwide is approximately 300 and 900 products, respectively.
The combination of the BIOLASE installed base of more than 19,000
lasers among 16,000 customers, brand recognition and marketing
expertise with the NewTom reputation for quality and performance was
the driving force for the agreement, said Sergio Ghezzi, global
managing director of Cefla Dental's NewTom imaging division.
"We have made a strong commitment to establish ourselves as a
substantial competitor in the North American 3D CBCT imaging market
and consider BIOLASE an ideal partner to accomplish that goal," Ghezzi
said. "Working closely with BIOLASE, we believe we can sustain growth
in our NewTom U.S. business unit while bringing the dental community
the highest quality 3D imaging products in the world."
Federico Pignatelli, BIOLASE Chairman and CEO, noted that the NewTom
products will nicely complement the state-of-the-art BIOLASE DaVinci
Imaging dental imaging devices and provide dental customers a wider
and more comprehensive choice of configurations, range of performance
and price points.
"The NewTom CBCT is widely known as the finest 3D imaging unit in the
world," Pignatelli said. "NewTom is a great brand and a great
technology with market-leading products which will nicely augment our
suite of highly respected, advanced imaging products and market
leading lines of diode and all-tissue lasers. We've named this
integration of lasers and imaging the Total Technology Solution with
the motto, 'See More-Do More.' The better the 3D imaging capabilities
of the dental professional, the earlier the diagnosis and the more
indications that can be identified and treated minimally invasively
with our Waterlase iPlus and iLase laser technologies, in many cases
without the use of anesthesia, in a very biologically friendly
fashion.
"This partnership is a nice fit for both companies including select
other international markets and should also provide us with an
entryway into a new and expansive source of revenue from the
periodontic, endodontic and oral surgery markets," Pignatelli
concluded.
The NewTom Cone Beam 3D imaging products will be featured in BIOLASE's
Booth (?1237) at the annual Chicago Dental Society Midwinter Meeting
being held February 23-25.
About Cefla Dental GroupThe company manufactured the world's first
CBCT scanner in 1997 and NewTom has since become the global leader in
maxillofacial and medical CBCT application technology. Located in
Verona, Italy, NewTom is part of Cefla s.c., a market leader in
production and marketing of a wide range of dental brands such as
treatment center and chair lines Anthos, Castellini, SternWeber and
Victor, as well as imaging brands NewTom and MyRay. For more
information, readers are encouraged to visit
www.newtom.us(http://www.newtom.us/) or call the company at
+1-704-731-5293.
About BIOLASE Technology, Inc.BIOLASE Technology, Inc., the World's
leading Dental Laser Company, is a medical technology company that
develops, manufactures and markets dental lasers and also distributes
and markets dental imaging equipment, products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's laser products incorporate 284 patented and patent pending
technologies designed to provide clinically superior performance with
less pain and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications, and a full line
of dental imaging equipment. Other products under development address
ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find
BIOLASE at http://www.biolase.com(http://www.biolase.com/), Twitter at
http://twitter.com/GoWaterlase(http://twitter.com/GoWaterlase), and
YouTube at
http://www.youtube.com/user/Rossca08(http://www.youtube.com/user/Rossca08).
This press release may contain forward-looking statements within the
meaning of safe harbor provided by the Securities Reform Act of 1995
that are based on the current expectations and estimates by our
management. These forward-looking statements can be identified through
the use of words such as "anticipates," "expects," "intends," "plans,"
"believes," "seeks," "estimates," "may," "will," and variations of
these words or similar expressions. Forward-looking statements are
based on management's current, preliminary expectations and are
subject to risks, uncertainties and other factors which may cause the
Company's actual results to differ materially from the statements
contained herein, and are described in the Company's reports it files
with the Securities and Exchange Commission, including its annual and
quarterly reports. No undue reliance should be placed on
forward-looking statements. Such information is subject to change, and
we undertake no obligation to update such statements.
